Eli Lilly reports 79 percent response rate as Eli Lilly and Co. stock trades at EUR 1137.60
Published on 10/25/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOvarian cancer data and dates
- Eli Lilly reported a 79.00 percent response rate and 100.00 percent disease-control rate on October 24, 2026.
- Eli Lilly and Co. stock trades at EUR 1137.60, 0.61 percent below the October 23, 2026, Xetra close of EUR 1144.60.
- The next Xetra session is scheduled for October 26, 2026.
On October 24, 2026, Eli Lilly and Company announced Phase 1 data for sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer. The combination produced a confirmed objective response rate of 79.00 percent and a disease-control rate of 100.00 percent, according to PR Newswire.
At 5:15 p.m. CEST on October 25, 2026, Eli Lilly and Co. stock traded in weekend trading at Lang & Schwarz at EUR 1137.60, or 0.61 percent below the Xetra close of October 23, 2026, at EUR 1144.60.
Weekend trading
The Lang & Schwarz quote showed a bid of EUR 1136.80 and an ask of EUR 1138.40 at the stated time. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
Market context: Market report S&P 500.
Last Xetra session
The Xetra close on October 23, 2026, was EUR 1144.60. The Lang & Schwarz weekend-trading price was therefore EUR 7.00 lower than that reference level.
Recent oncology announcement
Lilly said the ovarian cancer data came from 29 patients with measurable disease in a Phase 1 study. The company reported six complete responses and 17 partial responses, with activity observed across folate receptor alpha expression levels and regardless of prior PARP inhibitor exposure. Sofetabart mipitecan is being evaluated in the Phase 3 FRAmework-01 program, according to PR Newswire.
Next Xetra session
The next Xetra session is scheduled for October 26, 2026. Lilly's investor-relations release dated October 18, 2026, said additional oncology data were scheduled for presentation at the European Society for Medical Oncology Congress in Madrid through October 27, 2026, as reported by Eli Lilly investor relations.
